Another study reported that, after 53.3 months of treatment with belimumab, 9.7% of patients had a negative conversion of serum antinuclear antibody (ANA), which was then associated with a reduced risk of future SLE recurrence.14 This evidence concerns the gene BTG3 and systemic lupus erythematosus.